These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 1605292)

  • 21. Efficacy and safety of a seven-day, transdermal estradiol drug-delivery system: comparison with conjugated estrogens and placebo. The Transdermal Estradiol Patch Study Group.
    Gordon SF; Thompson KA; Ruoff GE; Imig JR; Lane PJ; Schwenker CE
    Int J Fertil Menopausal Stud; 1995; 40(3):126-34. PubMed ID: 7663539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy, safety and acceptability of a seven-day, transdermal estradiol patch for estrogen replacement therapy.
    Jarupanich T; Lamlertkittikul S; Chandeying V
    J Med Assoc Thai; 2003 Sep; 86(9):836-45. PubMed ID: 14649968
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The long-term tolerability and efficacy of OESCLIM: results of a 1-year study.
    Taurelle R; L'Hermite M; Haenggi W; Lauritzen C; Studd JW
    Maturitas; 1999 Nov; 33 Suppl 1():S73-81. PubMed ID: 10661618
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.
    Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ
    Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alternatives to oral estrogen replacement. Transdermal patches, percutaneous gels, vaginal creams and rings, implants, other methods of delivery.
    Baker VL
    Obstet Gynecol Clin North Am; 1994 Jun; 21(2):271-97. PubMed ID: 7936545
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transdermal estrogen therapy.
    Connell EB
    Postgrad Med; 1997 Jun; 101(6):115-6, 122, 128-30 passim. PubMed ID: 9194869
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The smallest available estradiol transdermal patch: a new treatment option for the prevention of postmenopausal osteoporosis.
    Bertonazzi A; Nelson B; Salvador J; Umland E
    Womens Health (Lond); 2015 Nov; 11(6):815-24. PubMed ID: 26618621
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transdermal estroprogestins versus transdermal estrogen plus oral dihydrogesterone replacement in menopause.
    Marchesoni D; Dal Pozzo M; Dal Magro L; Paternoster DM; Ferroni E; Maggino T; Romagnolo C; Mozzanega B
    J Endocrinol Invest; 1996 May; 19(5):268-72. PubMed ID: 8796334
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oestrogen replacement after oophorectomy: comparison of patches and implants.
    Anderson CH; Raju SK; Forsling ML; Wheeler MJ
    BMJ; 1992 Jul; 305(6845):90-1. PubMed ID: 1449552
    [No Abstract]   [Full Text] [Related]  

  • 30. Menostar - a low-dose estrogen patch for osteoporosis.
    Med Lett Drugs Ther; 2004 Aug; 46(1190):69-70. PubMed ID: 15375352
    [No Abstract]   [Full Text] [Related]  

  • 31. Thrombotic thrombocytopenic purpura and 17 beta-estradiol transdermal skin patch.
    Liang R; Wong RW; Cheng IK
    Am J Hematol; 1996 Aug; 52(4):334-5. PubMed ID: 8701965
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinical experience with a 7-day estrogen patch: principles and practice.
    Notelovitz M
    Gynecol Endocrinol; 1998 Aug; 12(4):248-58. PubMed ID: 9798134
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Basic principles of hormone replacement therapy in the postmenopause].
    Dören M
    Ther Umsch; 2000 Oct; 57(10):628-34. PubMed ID: 11081374
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of efficacy and local tolerability of estradiol metered-dose transdermal spray to estradiol patch in a network meta-analysis.
    Kovács G; Zelei T; Vokó Z
    Climacteric; 2016 Oct; 19(5):488-95. PubMed ID: 27593417
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of estradiol and of estrone during application of a new 7-day estradiol transdermal patch with active matrix.
    Setnikar I; Rovati LC; Vens-Cappell B; Hilgenstock C
    Arzneimittelforschung; 1998 Mar; 48(3):275-85. PubMed ID: 9553686
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estradiol and estrone plasma levels during application of three strengths of a 7-day estradiol transdermal patch.
    Setnikar I; Rovati LC; Santoro A; Guillaume M; Mignot A; Renoux A; Gualano V
    Arzneimittelforschung; 1999 Aug; 49(8):708-15. PubMed ID: 10483519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized study to compare the effectiveness, tolerability, and acceptability of two different transdermal estradiol replacement therapies. The Transdermal HRT Investigators Group.
    Int J Fertil Menopausal Stud; 1993; 38(1):5-11. PubMed ID: 8485612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transdermal menopausal hormone therapy: delivery through skin changes the rules.
    Buster JE
    Expert Opin Pharmacother; 2010 Jun; 11(9):1489-99. PubMed ID: 20426703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allergic contact dermatitis from transdermal estradiol and systemic contact dermatitis from oral estradiol. A case report.
    Corazza M; Mantovani L; Montanari A; Virgili A
    J Reprod Med; 2002 Jun; 47(6):507-9. PubMed ID: 12092023
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A review of transdermal nonpatch estrogen therapy for the management of menopausal symptoms.
    Carroll N
    J Womens Health (Larchmt); 2010 Jan; 19(1):47-55. PubMed ID: 20088658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.